Literature DB >> 9029046

Induction of two UDP-glucuronosyltransferase isoforms sensitive to phenobarbital that are involved in morphine glucuronidation: production of isoform-selective antipeptide antibodies toward UGT1.1r and UGT2B1.

Y Ishii1, A Takami, K Tsuruda, A Kurogi, H Yamada, K Oguri.   

Abstract

We document here in that two UDP-glucuronosyltransferase (UGT) isoforms sensitive to phenobarbital are involved in morphine glucuronidation in Wistar and Sprague-Dawley rats. The hepatic microsomal morphine UGT activity in untreated Gunn rats was significantly less than that of untreated Wistar rats. Although the morphine UGT activity in the liver of Gunn rats was increased by phenobarbital (PB) treatment, this was significantly less than that in the liver of PB-treated Wistar rats. UGT1.1r is an isoform of morphine UGT in rat, and UGT2B1 is also considered an isoform of morphine UGT, because UGT2B1 (stably expressed in V79 cells) exhibited morphine UGT activity. We prepared specific antipeptide antibodies against UGT1.1r and UGT2B1. Using isoform-specific antipeptide antibodies, both UGT1.1r and UGT2B1 in Wistar and Sprague-Dawley rats were inducible by PB treatment. However, UGT1.1r is not present in the liver from Gunn rats. This study is the first demonstration that protein levels of two morphine UGT isoforms, UGT1.1r and UGT2B1, in the liver of Wistar and Sprague-Dawley rats are inducible by PB treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029046

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells.

Authors:  A Galijatovic; U K Walle; T Walle
Journal:  Pharm Res       Date:  2000-01       Impact factor: 4.200

2.  Prevalence of UDP-glucuronosyltransferase polymorphisms (UGT1A6∗2, 1A7∗12, 1A8∗3, 1A9∗3, 2B7∗2, and 2B15∗2) in a Saudi population.

Authors:  Khalid M Alkharfy; Basit L Jan; Sibtain Afzal; Fahad I Al-Jenoobi; Abdullah M Al-Mohizea; Saleh Al-Muhsen; Rabih Halwani; Mohammad K Parvez; Mohammed S Al-Dosari
Journal:  Saudi Pharm J       Date:  2016-06-02       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.